
Aktiviere Job-Benachrichtigungen per E-Mail!
Erstelle in nur wenigen Minuten einen maßgeschneiderten Lebenslauf
Überzeuge Recruiter und verdiene mehr Geld. Mehr erfahren
A global biopharmaceutical company is seeking a Senior Manager of Drug Substance MSAT in Zug, Switzerland. The role involves leading tech transfer, process optimization, and validation at manufacturing sites, requiring extensive cGMP experience and a strong MSAT background. The successful candidate will collaborate with cross-functional teams and have expertise in process development and lifecycle management. This position offers the chance to contribute to innovative therapies in a dynamic environment, with flexible working arrangements.
Apellis Pharmaceuticals
Location: Zug, Switzerland (requires 2‑3 days office presence per week)
Employment type: Full‑time, Mid‑Senior level
Job Function: Other
As part of the MSAT team, the Senior Manager of Drug Substance (DS) Manufacturing Science and Technology (MSAT) will lead tech transfer, process qualification, and validation at contract drug substance manufacturing sites. Responsibilities include process scalability, PPQ, monitoring, optimization, and manufacturability of drug substance and key intermediates. The role requires broad expertise in manufacturing and late‑stage/commercial operations, supporting cross‑functional teams. Technical support will be provided for both late‑stage lifecycle and early‑stage pipeline projects.
Valid passport and ability to travel.
Bachelor's Degree
Apellis offers a comprehensive benefits package, inclusive flexible time off, summer and winter shutdowns, paid family leave and more!
Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company leading the way in complement science to develop life‑changing therapies for some of the most challenging diseases patients face. We ushered in the first new class of complement medicine in 15 years and now have two C3‑targeting medicines approved to treat four serious diseases. Breakthroughs for patients include the first‑ever therapy for geographic atrophy, a leading cause of blindness, and the first treatment for patients 12 and older with C3G or primary IC‑MPGN, two severe, rare kidney diseases. We believe we have only begun to unlock the potential of targeting C3 across many serious diseases.
Please note this job description is not designed to cover or contain a comprehensive listing of activities, duties or responsibilities that are required of the employee for this job. Duties, responsibilities and activities may change at any time with or without notice.